Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schulman, S.
Right arrow Articles by Beyth, R. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schulman, S.
Right arrow Articles by Beyth, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation

Sam Schulman1,2,* and Rebecca J. Beyth3,4

1McMaster Clinic, HHS—General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
2Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
3Geriatrics Division, Department of Medicine, University of Florida, Gainesville, FL, USA
4Malcolm Randall VA Medical Center and Rehabilitation Outcomes Research Center, Gainesville, FL, USA

* Corresponding author. Tel: +1 905 528 9946; fax: +1 905 5211551. E-mail address: schulms{at}mcmaster.ca

The fear of bleeding complications is a common reason for withholding effective prophylaxis with vitamin K antagonists (VKAs) against thromboembolism. This article reviews the epidemiology of bleeding complications with VKAs, with particular emphasis on studies in patients with atrial fibrillation. Risk factors for bleeding, which can be divided into those related to excessive anticoagulant effect and/or those related to increased patient susceptibility, are discussed. The strongest risk factors can be built into models for predicting bleeding during anticoagulant therapy, and two such models that have been published are described. Finally, effective corrective treatment of excessive anticoagulation and bleeding episodes, that are crucial for the outcome and different modalities, are also reviewed.

Key Words: Anticoagulation • Bleeding • Atrial fibrillation • Reversal • Prediction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Circ Cardiovasc Qual OutcomesHome page
D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go
Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study
Circ Cardiovasc Qual Outcomes, July 1, 2009; 2(4): 297 - 304.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.